Azalanstat

Drug Profile

Azalanstat

Alternative Names: RS 21607; RS 21607-007; RS 21607-197

Latest Information Update: 14 Nov 2006

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Roche
  • Class Antihyperlipidaemics
  • Mechanism of Action 14-alpha demethylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hyperlipidaemia

Most Recent Events

  • 01 Jun 1999 No-Development-Reported for Hyperlipidaemia in Switzerland (PO)
  • 01 Jun 1999 No-Development-Reported for Hyperlipidaemia in USA (PO)
  • 08 Nov 1995 Animal studies have been added to the pharmacodynamics section for Antihyperlipidaemics .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top